DB:12X1

Stock Analysis Report

Executive Summary

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Anavex Life Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 12X1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.9%

12X1

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

-6.0%

12X1

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 12X1 exceeded the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 12X1 exceeded the German Market which returned -20.9% over the past year.


Shareholder returns

12X1IndustryMarket
7 Day-9.9%-0.7%-0.6%
30 Day-34.1%-8.2%-18.6%
90 Day-9.2%-21.0%-26.2%
1 Year-6.0%-6.0%-12.9%-13.2%-18.6%-20.9%
3 Year-55.0%-55.0%14.5%13.2%-19.0%-25.8%
5 Yearn/a-9.5%-11.8%-21.2%-31.8%

Price Volatility Vs. Market

How volatile is Anavex Life Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Anavex Life Sciences undervalued compared to its fair value and its price relative to the market?

5.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 12X1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 12X1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 12X1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 12X1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 12X1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 12X1 is overvalued based on its PB Ratio (5.8x) compared to the DE Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Anavex Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-11.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 12X1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 12X1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 12X1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 12X1's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 12X1's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 12X1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Anavex Life Sciences performed over the past 5 years?

-15.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 12X1 is currently unprofitable.

Growing Profit Margin: 12X1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 12X1 is unprofitable, and losses have increased over the past 5 years at a rate of -15.9% per year.

Accelerating Growth: Unable to compare 12X1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 12X1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 12X1 has a negative Return on Equity (-100.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Anavex Life Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: 12X1's short term assets ($31.4M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: 12X1 has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 12X1 is debt free.

Reducing Debt: 12X1 has no debt compared to 5 years ago when its debt to equity ratio was 61.2%.


Balance Sheet

Inventory Level: 12X1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 12X1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 12X1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 12X1 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -33% each year.


Next Steps

Dividend

What is Anavex Life Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 12X1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 12X1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 12X1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 12X1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 12X1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Chris Missling (53yo)

6.75s

Tenure

US$3,380,039

Compensation

Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial  ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD3.38M) is above average for companies of similar size in the German market ($USD744.69K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Missling
Chairman6.75yrsUS$3.38m1.74% $2.5m
Sandra Boenisch
Principal Financial Officer & Treasurer4.5yrsUS$224.56k0.039% $55.8k
Stephan Toutain
Chief Operating Officer2.08yrsno datano data
Emmanuel Fadiran
Senior Vice President of Regulatory Affairsno datano datano data
Walter Kaufmann
Chief Medical Officerno datano datano data
Clint Tomlinson
Executiveno datano datano data

4.5yrs

Average Tenure

53yo

Average Age

Experienced Management: 12X1's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Missling
Chairman6.75yrsUS$3.38m1.74% $2.5m
Jeffrey Cummings
Member of the Scientific Advisory Board9.08yrsno datano data
Paul Aisen
Member of the Scientific Advisory Board9.17yrsno datano data
John Harrison
Member of the Scientific Advisory Board6.33yrsno datano data
Ottavio Arancio
Member of the Scientific Advisory Board6.42yrsno datano data
Tangui Maurice
Member of the Scientific Advisory Boardno datano datano data
Elliot Favus
Independent Director5.92yrsUS$93.87kno data
Athanasios Skarpelos
Independent Director7.25yrsUS$93.87k2.23% $3.2m
Norman Relkin
Member of the Scientific Advisory Board5.92yrsno datano data
Claus van der Velden
Independent Director2.08yrsUS$109.87kno data

6.4yrs

Average Tenure

52yo

Average Age

Experienced Board: 12X1's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.


Top Shareholders

Company Information

Anavex Life Sciences Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Anavex Life Sciences Corp.
  • Ticker: 12X1
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$153.702m
  • Listing Market Cap: US$142.467m
  • Shares outstanding: 58.66m
  • Website: https://www.anavex.com

Number of Employees


Location

  • Anavex Life Sciences Corp.
  • 51 West 52nd Street
  • 7th Floor
  • New York
  • New York
  • 10019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AVXLNasdaqCM (Nasdaq Capital Market)YesCommon SharesUSUSDApr 2006
12X1DB (Deutsche Boerse AG)YesCommon SharesDEEURApr 2006
0HFRLSE (London Stock Exchange)YesCommon SharesGBUSDApr 2006
12X1BRSE (Berne Stock Exchange)YesCommon SharesCHCHFApr 2006

Biography

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company’s lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase II clinical trials to treat Parkinson’s disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer’s and Parkinson’s diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 02:45
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.